Relearning the Lessons of Genomic Stability of Human Cells During Expansion in Culture: Implications for Clinical Research
Open accessThe DOI matches its Crossref record.
Abstract
The new technologies for analyzing the genomes of cells will certainly provide exciting new data to help unravel some of the major mysteries of biology. At the same time, some of the data simply allow us to rediscover principles that were defined long ago. For example, a recent publication reported that an analysis of gene expression data demonstrated that “neural and mesenchymal stem cells acquire characteristic large chromosomal abnormalities at a similar, or somewhat lower, frequency to that seen in pluripotent stem cells, sometimes within a few passages in culture” [1]. But are these results surprising? Do they blur over a critical distinction among different cells in culture? Do they mean that, as the authors conclude, “..validating the genomic stability of stem cells of all types in culture is crucial …for their safe implementation in cell therapy.” Therefore, will it be necessary to perform extensive genomic analysis on all culture-expanded cells before they can be used safely in patients? Or have we been here before when observing cells in culture? Concern about the chromosomal stability of cells in culture arose over 40 years ago when Wi-38 human fibroblasts were first introduced by Hayflick et al. [2] as substrates for viruses to develop vaccines. Manufacturers of vaccines were required to ensure that the cells were free, not only of any adventitious agents but also of what were then referred to as “any neoplastic properties.” As result, beginning in the 1960s, manufacturers were required to test the cells by karyotyping of chromosomes in addition to assaying for tumors after injection into immunodeficient mice. A number of chromosomal abnormalities in cultured Wi-38 cells were quickly detected by the crude karyotyping assays available at the time. However, there was considerable confusion about the significance of the changes. An International Committee that met in Geneva in 1976 could not agree on karyotypic criteria that should be applied for use of the cells [3] and the confusion continued for many years. For example, analysis of 18 cell banks revealed a chromosome 7;12 translocation with a frequency of 0.2%–5.6% in the diploid fibroblasts used to produce vaccines, both Wi-38 cells and similar cells referred to as MRC-5 [4]. However, the translocation was rarely seen at low population doublings (PDLs <30), increased with expansion to reach a plateau at 40-50 PDLs, and disappeared when cultures became senescent. Most importantly, there were no differences in growth characteristics or in tumorigenicity in mice between the cultures that did or did not contain t(7;12). The interpretation of data on chromosomal stability has been further complicated by the recent widespread use of invasive prenatal diagnosis. Assays with array-assisted comparative genomic hybridization detected copy number variation of unknown significance in 0.5%–1% of samples [5]. In addition, copy number variations of genes were found to be common and as high as 12% of the human genome. Where does this leave us in evaluating the potential dangers of therapies with cells that are expanded in culture? One guideline is provided by more than three decades of experience using culture-expanded human fibroblasts for vaccine production and by cell karyotyping and testing tumorigenicity in mice. One opinion was the “futility of continuing to do these tests is obvious” [6]. Another opinion was that after initial tests to establish the identity of the cells, chromosomal analysis should not be required before using the cells as substrates for the manufacture of live virus vaccines [4]. What are the appropriate tests? Given that most human cancer cells do not produce tumors in immune deficient mice, the assay for tumorigenicity using nude mice has unacceptably low sensitivity. For example, despite intensive efforts, it has not been possible to develop a mouse model with orthotopic implantation of human osteosarcoma cells that mimics the human disease [7]. At the end of the day, the most reliable test is one of the simplest [8, 9]: do the cells senesce in culture? If they do, they are unlikely to produce tumors or malignancies in patients. Unlikely in the sense that there is a low probability, but not a certainty, that the expanded cultures do not contain a few cells that have acquired an oncogenic mutation. In contrast, cells that are immortal in culture carry a serious risk. Unfortunately, at present, there is no strategy for eliminating this risk. Differentiating the cells in such cultures, or cloning and then differentiating them, does not eliminate the risk as there is no current technology, or any method on the horizon, to detect a few tumorigenic cells in the large-scale cultures that are required for most therapeutic applications. In considering any therapy, we always return to the same question: what is the probability of benefiting versus harming the patient? We can answer this question with greater confidence as our knowledge of bi
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mesenchymal stromal cells: new directions
Keating, A. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.015 · Cited by 778
Self-citationKim, D.-K., Nishida, H., An, S. Y., Shetty, A. K., Bartosh, T. J., & Prockop, D. J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522297113 · Cited by 433
Self-citationWang, Y., Zhang, Z., Chi, Y., Zhang, Q., Xu, F., Yang, Z., Meng, L., Yang, S., Yan, S., Mao, A., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.480 · Cited by 185
“No immortalization or malignant transformation was observed in the present study, which was consistent with the result observed in the study of BMMSCs.13,36 Previous researches paid much attention on the genomic stability of cultured MSCs. Based on traditional karyotype analysis, some studies found that abnormal karyo…”
ResultChoi, J. R., Pingguan-Murphy, B., Wan Abas, W. A. B., Yong, K. W., Poon, C. T., Noor Azmi, M. A., Omar, S. Z., Chua, K. H., Xu, F., & Wan Safwani, W. K. Z. (2015) · PLOS ONE · doi:10.1371/journal.pone.0115034 · Cited by 63
Metadata
- Authors
- Prockop, D. J., & Keating, A.
- Venue
- Stem Cells
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-05-15
- Volume
- 30
- Issue
- 6
- Pages
- 1051-1052
- ISSN
- 1066-5099 (ISSN-L)
- 1549-4918
- OpenAlex
- W2078858529
- Cited by
- 39
- References
- 0
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Relearning the Lessons of Genomic Stability of Human Cells During Expansion in Culture: Implications for Clinical Research. https://app.cochat.ai/papers/10.1002/stem.1103
- The paper
- Prockop, D. J., & Keating, A. (2012). Relearning the Lessons of Genomic Stability of Human Cells During Expansion in Culture: Implications for Clinical Research. Stem Cells. https://doi.org/10.1002/stem.1103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.